Preliminary results of phase I clinical trial of high doses of seleno-L-methionine (SLM) in sequential combination with axitinib in previously treated and relapsed clear cell renal cell carcinoma (ccRCC) patients.
Rohan Garje(Baptist Hospital of Miami), Yousef Zakharia(University of Iowa), Sarah L. Mott(University of Iowa), Andrew M. Bellizzi(University of Iowa), Kenneth G. Nepple(University of Iowa), Douglas Laux(University of Iowa Hospitals and Clinics), Jaime Bonner(University of Iowa), James A. Brown(University of Iowa Health Care), Mohammed Milhem(University of Iowa), Laila Dahmoush(University of Iowa), Youcef M. Rustum(University of Iowa), Gideon Zamba(University of Iowa)
Cited by 5
Related Papers
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2021|411
Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue
|JAMA Oncology|2022|347
Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma
|Journal of Surgical Oncology|2014|274